Latest News

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

Eugene Wright, Jr., MD, joins the show to discuss the current state of technological integration into diabetes care, from glucose monitors to insulin delivery and beyond.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

The CONNECT trial found CGM improved A1C and time in range in adults with type 2 diabetes not on insulin.

STEP UP T2D data suggest semaglutide 7.2 mg's superiority to the 2.4 mg dose and placebo for proposed BMI and waist-to-height ratio treatment targets.

An EHR-based machine learning model predicted 10-year type 2 diabetes risk with near-ideal calibration in over 3 million adult patients.

New findings point to remaining gaps in AI diagnostic success for skin lesions compared with experienced clinicians in dermatology.

From hepatitis D's first FDA-approved therapy to advances in hepatitis B and PBC, May delivered major developments in hepatology.

From FDA-approved at-home TMS and accelerated protocols to conversational AI matching group therapy outcomes, here are 5 psychiatry updates from May every clinician should know.

ACCESS phase 2b data show aleniglipron 120 mg produced 11.3% placebo-adjusted weight loss at 36 weeks, with continued reductions in the OLE.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

This Q&A interview highlights findings on the lifelong impacts on education and career faced by some patients with childhood diagnoses of atopic dermatitis.

Hear Jim Januzzi, MD, discuss how he overcame academic shortcomings to become one of the preeminent voices in cardiology biomarkers.

Catch up on major trial results, key FDA decisions, and more.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.